Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Nephrotisches Syndrom-Studiennetzwerk (NEPTUNE)

5. November 2026 aktualisiert von: Matthias Kretzler, University of Michigan

Nephrotisches Syndrom-Studiennetzwerk im Rahmen des Klinischen Forschungsnetzwerks für seltene Krankheiten

Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients.

In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium.

Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Idiopathic Nephrotic Syndrome (NS) is a rare disease syndrome responsible for approximately 12% of all causes of end-stage kidney disease (ESRD) and up to 20% of ESRD in children. Treatment strategies for Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD) and Membranous Nephropathy (MN), the major causes of NS, include high dose prolonged steroid therapy, cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate mofetil and other immunosuppressive agents, which all carry significant side effects. Failure to obtain remission using the current treatment approaches frequently results in progression to ESRD with its associated costs, morbidities, and mortality. In the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, half of the pediatric patients with Steroid Resistant Nephrotic Syndrome required renal replacement therapy within two years of being enrolled in the disease registry. FSGS also has a high recurrence rate following kidney transplantation (30-40%) and is the most common recurrent disease leading to allograft loss.

The prevailing classification of Nephrotic Syndrome categorizes patients into FSGS, MCD, and MN, if in the absence of other underlying causes, glomerular histology shows a specific histological pattern. This classification does not adequately predict the heterogeneous natural history of patients with FSGS, MCD, and MN. Major advances in understanding the pathogenesis of FSGS and MCD have come over the last ten years from the identification of several mutated genes responsible for causing Steroid Resistant Nephrotic Syndrome (SRNS) presenting with FSGS or MCD histopathology in humans and model organisms. These functionally distinct genetic disorders can present with indistinguishable FSGS lesions on histology confirming the presence of heterogeneous pathogenic mechanisms under the current histological diagnoses.

The limited understanding of FSGS, MCD, and MN biology in humans has necessitated a descriptive classification system in which heterogeneous disorders are grouped together. This invariably consigns these heterogeneous patients to the same therapeutic approaches, which use blunt immunosuppressive drugs that lack a clear biological basis, are often not beneficial, and are complicated by significant toxicity. The foregoing shortcomings make a strong case that concerted and innovative investigational strategies combining basic science, translational, and clinical methods should be employed to study FSGS, MCD, and MN. It is for these reasons that the Nephrotic Syndrome Study Network is established to conduct clinical and translational research in patients with FSGS/MCD and MN.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

1200

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • Ontario
      • Richmond Hill, Ontario, Kanada, L4C 4Z3
        • Abgeschlossen
        • York Central Hospital
      • Scarborough Village, Ontario, Kanada, M1H 3G4
        • Abgeschlossen
        • Scarborough Hospital
      • Toronto, Ontario, Kanada, M4N 3M5
      • Toronto, Ontario, Kanada, L5M 2N1
        • Rekrutierung
        • Credit Valley Hospital
        • Unterermittler:
          • Phillip Boll, MD
        • Kontakt:
      • Toronto, Ontario, Kanada, M5G2C4
        • Rekrutierung
        • University Health Network
        • Kontakt:
        • Kontakt:
        • Hauptermittler:
          • Daniel Cattran, MD
        • Unterermittler:
          • Heather Reich, MD
        • Unterermittler:
          • Michelle Hladunewich, MD
    • California
      • Los Angeles, California, Vereinigte Staaten, 90227
        • Rekrutierung
        • University of Southern California-Children's Hospital
        • Hauptermittler:
          • Kevin Lemley, MD, PhD
        • Kontakt:
      • Palo Alto, California, Vereinigte Staaten, 94304
        • Rekrutierung
        • Stanford University School of Medicine
        • Kontakt:
        • Hauptermittler:
          • Richard Lafayette, MD
      • San Francisco, California, Vereinigte Staaten, 94158
        • Noch keine Rekrutierung
        • University of California San Francisco Benioff Children's Hospitals
        • Hauptermittler:
          • Paul Brakeman, MD, PhD
        • Kontakt:
      • Torrance, California, Vereinigte Staaten, 90502
        • Rekrutierung
        • Lundquist Biomedical Research Institute at Harbor UCLA Medical Center
        • Kontakt:
        • Hauptermittler:
          • Sharon Adler, MD
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • Noch keine Rekrutierung
        • University of Colorado Anschutz School of Medicine
        • Hauptermittler:
          • Amber Podoll, MD
        • Kontakt:
    • Florida
      • Miami, Florida, Vereinigte Staaten, 33136
        • Rekrutierung
        • University of Miami Miller School of Medicine
        • Kontakt:
        • Hauptermittler:
          • Alessia Fornoni, MD. PhD
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Rekrutierung
        • Emory University and Children's Healthcare of Atlanta
        • Hauptermittler:
          • Laurence Greenbaum, MD, PhD
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60680
        • Rekrutierung
        • John Stroger Cook County Hospital
        • Kontakt:
        • Hauptermittler:
          • Ambarish Athavale, MD
    • Kansas
      • Kansas City, Kansas, Vereinigte Staaten, 66160
        • Rekrutierung
        • University of Kansas Medical Center
        • Kontakt:
        • Hauptermittler:
          • Ellen McCarthy, MD
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21287
        • Rekrutierung
        • Johns Hopkins Medical Institute
        • Kontakt:
        • Hauptermittler:
          • Alicia Neu, MD
        • Unterermittler:
          • Michael Choi, MD
      • Bethesda, Maryland, Vereinigte Staaten, 20892
        • Abgeschlossen
        • Kidney Disease Section, NIDDK, NIH
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48109
        • Rekrutierung
        • University of Michigan Medical Center
        • Kontakt:
        • Hauptermittler:
          • Matthias Kretzler, MD
        • Kontakt:
          • Amanda Williams, BS - adult
          • Telefonnummer: 734-615-5017
          • E-Mail: amwi@umich.edu
      • Ann Arbor, Michigan, Vereinigte Staaten, 48109
        • Rekrutierung
        • CS Mott Children's Hospital, University of Michigan
        • Unterermittler:
          • Debbie Gipson, MD, MS
        • Kontakt:
    • Minnesota
      • Rochester, Minnesota, Vereinigte Staaten, 55905
        • Abgeschlossen
        • Mayo Clinic
    • Missouri
      • Kansas City, Missouri, Vereinigte Staaten, 64108
        • Rekrutierung
        • Children's Mercy Hospital
        • Hauptermittler:
          • Tarak Srivastava, MD
        • Kontakt:
      • St Louis, Missouri, Vereinigte Staaten, 63110
        • Noch keine Rekrutierung
        • Washington University - St Louis
        • Kontakt:
        • Hauptermittler:
          • Vikas Dharnidharka, MD, PhD
    • New York
      • New Hyde Park, New York, Vereinigte Staaten, 11040
        • Rekrutierung
        • Cohen Children's Hospital
        • Hauptermittler:
          • Christine Sethna, MD
        • Kontakt:
      • New York, New York, Vereinigte Staaten, 10032
        • Rekrutierung
        • Columbia University Medical Center
        • Hauptermittler:
          • Andrew Bomback, MD, MPH
        • Kontakt:
      • New York, New York, Vereinigte Staaten, 10010
        • Rekrutierung
        • New York University Medical Center
        • Kontakt:
        • Hauptermittler:
          • Olga Zhadnova, MD
        • Hauptermittler:
          • Howard Trachtman, MD
        • Kontakt:
      • New York, New York, Vereinigte Staaten, 10016
        • Rekrutierung
        • Bellevue Hospital
        • Kontakt:
        • Hauptermittler:
          • Laura Barisoni, MD
        • Unterermittler:
          • Olga Zhadnova, MD
      • New York, New York, Vereinigte Staaten, 10016
        • Rekrutierung
        • New York University Veterans Administration
        • Kontakt:
        • Hauptermittler:
          • Laura Barisoni, MD
        • Unterermittler:
          • Olga Zhadnova, MD
      • The Bronx, New York, Vereinigte Staaten, 11040
        • Rekrutierung
        • Montefiore Medical Center
        • Kontakt:
        • Unterermittler:
          • Robert Woroniecki, MD
        • Hauptermittler:
          • Frederick Kaskel, MD
    • North Carolina
      • Chapel Hill, North Carolina, Vereinigte Staaten, 27599
        • Rekrutierung
        • University of North Carolina at Chapel Hill
        • Kontakt:
        • Hauptermittler:
          • Patrick H. Nachman, MD
        • Unterermittler:
          • Susan L. Hogan, PhD, MPH
        • Unterermittler:
          • Keisha Gibson, MD
        • Kontakt:
      • Charlotte, North Carolina, Vereinigte Staaten, 28203
        • Rekrutierung
        • Atrium Health Levine Children's Hospital
        • Hauptermittler:
          • Susan Massengill, MD
        • Kontakt:
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27157
        • Zurückgezogen
        • Wake Forest School of Medicine
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44195
        • Rekrutierung
        • Cleveland Clinic
        • Unterermittler:
          • Katherine Dell, MD
        • Kontakt:
        • Kontakt:
          • Villarreal
      • Cleveland, Ohio, Vereinigte Staaten, 44106
        • Abgeschlossen
        • University Hospital Rainbow Babies & Children's Hospital
      • Cleveland, Ohio, Vereinigte Staaten, 44109
        • Abgeschlossen
        • MetroHealth Hospital at Case Western Medical Center
      • Columbus, Ohio, Vereinigte Staaten, 43210
        • Rekrutierung
        • The Ohio State University Wexner Medical Center
        • Kontakt:
        • Hauptermittler:
          • Salem Almaani, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Rekrutierung
        • University of Pennsylvania
        • Kontakt:
        • Hauptermittler:
          • Lawrence Holzman, MD
        • Kontakt:
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Rekrutierung
        • Children's Hospital of Philadelphia
        • Unterermittler:
          • Kevin Meyers, MD
        • Kontakt:
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19140
        • Rekrutierung
        • Temple University
        • Kontakt:
        • Hauptermittler:
          • Crystal Gadegbeku, MD
        • Hauptermittler:
          • Iris Lee, MD
    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29425
        • Rekrutierung
        • Medical University of South Carolina
        • Hauptermittler:
          • David Selewski, MD, MS
    • Texas
      • Dallas, Texas, Vereinigte Staaten, 75390
      • Houston, Texas, Vereinigte Staaten, 77030
        • Rekrutierung
        • Texas Children's Hospital - Baylor College of Medicine
        • Kontakt:
        • Hauptermittler:
          • Shweta S. Shah, MD
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98195
      • Seattle, Washington, Vereinigte Staaten, 98145
      • Spokane, Washington, Vereinigte Staaten, 99204

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

Nicht älter als 80 Jahre (Kind, Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Patients with signs and symptoms of kidney disease consistent with FSGS, MCD, MN or proteinuric renal disease or pediatric participants not previously biopsied, who present for patient care at participating clinical centers will be eligible for Cohort A (biopsy cohort) study population targeted for enrollment into the NEPTUNE study.

To establish a cohort of pediatric participants with incident nephrotic syndrome, Cohort B, a non-biopsy cohort has been initiated for Protocol V4.0. This population, <19 years of age, presenting for nephrotic syndrome and less than 30 days of immunosuppression therapy exposure, will also be targeted for enrollment into the cNEPTUNE study.

Potential participants willing to receive their initial care and subsequent follow-up study visits at one of these sites are welcome to participate.

Beschreibung

Cohort A (biopsy cohort) Inclusion Criteria:

Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:

  • Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.
  • Scheduled renal biopsy

Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:

  • Age <19 years of age

  • Initial presentation with <30 days immunosuppression therapy

  • Proteinuria/nephrotic

    • UA>2+ and edema OR
    • UA>2+ and serum albumin <3 OR
    • UPC > 2g/g and serum albumin <3

Exclusion Criteria (Cohort A&B):

  • Prior solid organ transplant
  • A clinical diagnosis of glomerulopathy without diagnostic renal biopsy
  • Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)
  • Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)
  • Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months
  • Unwillingness or inability to give a comprehensive informed consent
  • Unwillingness to comply with study procedures and visit schedule
  • Institutionalized individuals (e.g., prisoners)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Beobachtungsmodelle: COHORT
  • Zeitperspektiven: PROSPECTIVE

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
FSGS/MCD Cohort (Cohort A)

Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort

Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.

Eligible participants must be scheduled for a clinically indicated renal biopsy.

Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

MN Cohort (Cohort A)

Membranous Nephropathy (MN) Cohort

Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.

Eligible participants must be scheduled for a clinically indicated renal biopsy.

Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

Other glomerulopathies cohort

Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.

Eligible participants must be scheduled for a clinically indicated renal biopsy.

Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

cNEPTUNE (Cohort B)

Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Event rate of change in urinary protein excretion and renal function.
Zeitfenster: 60 months

Defined as remission, partial remission and non-remission

60 months
Rate of change in renal function.
Zeitfenster: 60 months

Defined as:

  1. 25 mls/min/1.73m2 reduction in follow-up estimated GFR (using the 4-variable MDRD equation for ages ≥18 years and modified Schwartz for ages <18 years) compared to baseline estimated GFR
  2. 50% decline in follow-up estimated GFR compared to baseline measurement
  3. End stage renal disease defined as estimated GFR ≤10cc/min, initiation of maintenance dialysis or preemptive kidney transplantation.
60 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Quality of Life:
Zeitfenster: 60 months

Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals as stipulated in the visit calendar using the SF-36, PedsQL and the Patient Reported Outcome Measurement Information System (PROMIS) (in the age-appropriate groups).

60 months
Malignancies
Zeitfenster: 60 months

Any cancer diagnosis of the skin, hematopoietic system, or solid organ after enrollment in NEPTUNE

60 months
Infections, Serious and Systemic
Zeitfenster: 60 months

Infections including one of the following:

  1. Documented diagnosis of infection of the skin or subcutaneous tissue (e.g. cellulitis), vascular system, peritoneum, or any vital organ requiring the use of parenteral antibiotics and/or oral antibiotics alone or in combination for a treatment interval of ≥72 hours.
  2. Hospitalization for treatment of infection
60 months
Thromboembolic Events
Zeitfenster: 60 months

Documented diagnosis of one of the following:

  1. Embolic cerebrovascular accident
  2. Deep venous thrombosis
  3. Renal vein thrombosis or
  4. Pulmonary embolus
60 months
Hospitalization
Zeitfenster: 60 months

Documented hospital admission, including observation for ≥24 hours.

60 months
Emergency Department/ Observation Unit Visit
Zeitfenster: 60 months

Documented visit to an emergency department or observation unit that does not lead to hospitalization and is less than 24 hours.

60 months
Acute Kidney Injury
Zeitfenster: 60 months

Documented diagnosis of acute kidney injury as defined by the AKIN (Mehta et al., Critical Care 2007, 11:R31) and/or renal failure requiring renal replacement therapy <3 months.

60 months
Death
Zeitfenster: 60 months
  1. Documentation of death that is secondary to infection or sepsis.
  2. Cardiovascular/Cerebrovascular-related Death: Sudden death; Myocardial infarction; Congestive heart failure; Primary intractable serious arrhythmia; Peripheral vascular disease; Ischemic cerebrovascular accident; Hemorrhagic cerebrovascular accident; Thromboembolic event
  3. Documentation of death secondary to cancer
  4. Other Death: Documentation of death that does not fall into the above categories.
60 months
New Onset Diabetes
Zeitfenster: 60 months

Diagnosis of diabetes as indicated by 1 or more of the following not present at NEPTUNE Enrollment:

  1. Documented diagnosis of diabetes in medical record
  2. Casual (non-fasting) blood glucose > 200 mg/dL c) Fasting blood glucose > 126 mg/dL d) 2 hour glucose > 200 after oral glucose tolerance test e) chronic use (>6 mos) hypoglycemic therapy outside of pregnancy f) Hemogloblin A1C >= 6.5%
60 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Matthias Kretzler, MD, University of Michigan

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. April 2010

Primärer Abschluss (Geschätzt)

31. Dezember 2030

Studienabschluss (Geschätzt)

31. Dezember 2030

Studienanmeldedaten

Zuerst eingereicht

29. Juli 2010

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

23. September 2010

Zuerst gepostet (Geschätzt)

24. September 2010

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

10. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 6801
  • 1U54DK083912 (US NIH Stipendium/Vertrag)
  • 1R01DK141114-01A1 (US NIH Stipendium/Vertrag)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .